The vote of confidence is a stepping stone for the company to seek 510(k) approval for an H1N1 test on its platform; to tackle the point-of-care diagnostic market; and to further develop tests for other infectious diseases.
The San Antonio-based firm also intends to file a 510(k) for clearance of the assay.
The clearance covers a respiratory viral test for both RSV and hMPV.
Quidel said that Diagnostic Hybrids' fluorescent in vitro diagnostic assays would complement Quidel's point-of-care diagnostics for infectious disease and reproductive health.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.